Botulinum toxin type A (BOTOX) for treatment of migraine.
Semin Cutan Med Surg
; 20(2): 93-100, 2001 Jun.
Article
en En
| MEDLINE
| ID: mdl-11474749
ABSTRACT
An open-label study and 2 double-blind, placebo-controlled studies have provided supporting evidence of botulinum toxin type A (BTX-A) as an effective, well-tolerated treatment for migraine. Observed durations of benefit were consistent with known properties of BTX-A. Findings suggest that response may vary by features of preinjection headaches, such as migraine frequency. The precise mechanism by which BTX-A provides pain relief is hypothesized to be related not only to acetylcholine inhibition but also to a blocking action on the parasympathetic nervous system. Additional studies that control factors likely to be related to response may lead to better understanding of the BTX-A effect on migraine and an optimal treatment protocol.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Toxinas Botulínicas Tipo A
/
Trastornos Migrañosos
/
Fármacos Neuromusculares
Tipo de estudio:
Clinical_trials
/
Etiology_studies
/
Guideline
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Semin Cutan Med Surg
Asunto de la revista:
DERMATOLOGIA
Año:
2001
Tipo del documento:
Article
País de afiliación:
Estados Unidos